Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Stock Down 1.7 %

PCVX stock opened at $86.64 on Thursday. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06. The company has a market cap of $10.80 billion, a P/E ratio of -18.83 and a beta of 0.98. The business’s fifty day moving average is $87.49 and its 200-day moving average is $93.93.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the business posted ($0.91) earnings per share. Research analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its holdings in Vaxcyte by 12.3% in the second quarter. Envestnet Asset Management Inc. now owns 47,961 shares of the company’s stock worth $3,622,000 after purchasing an additional 5,268 shares during the period. Amalgamated Bank raised its stake in Vaxcyte by 4.2% during the 2nd quarter. Amalgamated Bank now owns 3,759 shares of the company’s stock worth $284,000 after buying an additional 150 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in Vaxcyte by 22.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 4,850 shares of the company’s stock worth $366,000 after acquiring an additional 895 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Vaxcyte in the second quarter worth about $1,053,000. Finally, Sei Investments Co. increased its holdings in shares of Vaxcyte by 64.5% in the second quarter. Sei Investments Co. now owns 170,149 shares of the company’s stock worth $12,848,000 after acquiring an additional 66,746 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.